Close Menu

Movers & Shakers: Aug 19, 2011

Premium

The Swiss Institute of Bioinformatics has appointed David de Graaf and Alexey Nesvizhskii to serve on its scientific advisory board.

De Graaf is CEO of Selventa. Prior to that he was vice president of biotherapeutics and integrative biology at Boehringer-Ingelheim. He has also held positions at Pfizer, AstraZeneca, and the Whitehead Institute's Center for Genome Research.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Sep
09
Sponsored by
10x Genomics

Recent advances in spatially resolved transcriptomics have greatly expanded the knowledge of complex multicellular biological systems.